摘要
2012年ESC发表了心力衰竭(心衰)诊治指南。与急性心衰和射血分数代偿心衰(HFpEF)有关的临床试验包括RELAX-AHF、Aldo-DHF、PARAMOUNT与RALY-DHF等。本文总结新指南和这些试验结果,探讨盐皮质激素受体拮抗剂是否适用于所有的心衰患者,急性心衰重组人松弛素2的应用,HFpEF治疗的探索,肾交感神经阻滞能否用于心衰,以及干细胞治疗缺血性心衰是否有效等热点问题。
In 2012 there were a number of important advances within the area of heart failure.The most relevant development is the 2012 publication of the European guideline for heart failure.In addition there were new clinical trials that focus on acute heart failure or heart failure with preserves EF,including RELAX-AHF,AldoDHF,PARAMOUNT,RALY-DHF trials.This article summarized the main heart failure highlights of the new guideline and those clinical trials,discussed the hot issues,such as should the benefits of MRAs extend to all patients Relax 2in acute heart failure,HFPEF treatment,and renal denervation or stem cell therapy in patients with heart failure.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2013年第4期241-243,共3页
Journal of Clinical Cardiology
关键词
心力衰竭
射血分数
盐皮质激素受体拮抗剂
松弛素
肾交感神经阻滞
干细胞治疗
heart failure
ejection fraction
mineralocorticoid receptor antagonist
serelaxin
renal sympathetic nerve block
stem cell therapy
